Navigation Links
OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
Date:10/13/2010

NEW YORK, Oct. 13 /PRNewswire/ -- OLIGOMERIX, Inc. announced today that Vic Micati, a Director since 2007, has been appointed Chairman of Oligomerix and that Jack Pasini has been appointed to the Company's Board of Directors and as Chief Commercial Officer.  

Having worked at Pfizer Inc. (PFE) for nearly 40 years, Mr. Micati was a member of Pfizer's Corporate Management Committee responsible for all aspects of global operations. He also served as Executive Vice President of the Pharmaceutical Group and Vice President of Pfizer Inc. He was appointed to the International Board of Directors in 1984 and became President of Pfizer's European operations in 1990.

Since 1999, Mr. Micati has worked as a consultant in the pharmaceutical industry and served on the board of several companies including Ilex Oncology (ILXO), subsequently acquired by Genzyme Corporation (GENZ), ENZON Pharmaceuticals Inc. (ENZN) and was member of the Advisory Board of Almirall, a Spanish pharmaceutical company.

Mr. Pasini is also a seasoned executive, having gained broad global commercial leadership experience during a 30-year career with Pfizer. Formerly, Mr. Pasini was Vice President, Worldwide Marketing responsible for Pfizer's Anti-Infective and Allergy/Respiratory Therapeutic Groups.  He also served as Vice President of Product Development, Regional President of the Africa, Middle East Region, and Vice President of Business Intelligence & Planning.  Mr. Pasini served on the board of the American Lung Association of the City of New York for five years.  Since his retirement in 2007, Mr. Pasini has worked as a consultant in the pharmaceutical industry.

"We are very pleased that Vic has agreed to take on the role of Chairman of Oligomerix and that Jack has agreed to join the Oligomerix Board and serve as Chief Commercial Officer.  We anticipate that Jack will play a key role in developing important partnerships within the industry to facilitate our transition into a full-scale biotechnology company," said James Moe, President & CEO.

ABOUT OLIGOMERIX

OLIGOMERIX, Inc. is a biopharmaceutical company founded in 2006 located within the Audubon Biomedical Science and Technology Park of Columbia University. The Company is exploiting its novel research that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases.  For more information visit www.oligomerix.com.Media Contact:Tiberend Strategic Advisors, Inc.212-827-0020Farrell Denbyfdenby@tiberendstrategicadvisors.com
'/>"/>

SOURCE OLIGOMERIX, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
2. Boston Scientific Announces Global Launch of Journey™ Guidewire
3. Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing Process
4. CORRECTED - Akorn, Inc. Announces Date Change for Third Quarter 2010 Earnings Release and Conference Call
5. Prime Therapeutics Announces URAC Accreditation
6. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
7. Cellectis bioresearch Announces Establishment of Subsidiary in the US
8. BioSpecifics Technologies Corp. Announces Initiation of Global Phase 3 Trial of XIAFLEX® for Treatment of Peyronies Disease
9. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
10. Misonix Announces Change in Distribution of SonaStar® Surgical Aspiration System in the U.S.
11. Express Scripts Announces Third Quarter 2010 Earnings and 2011 Earnings Guidance Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... Israel , May 31, 2016 CollPlant ... proprietary plant-based rhCollagen technology for tissue repair products - ... Scientist of Israel,s Ministry of ... million development project for 2016. The Chief Scientist,s grant amount ... authorized grant, which totaled NIS 4.7 million.  ...
(Date:5/31/2016)... PUNE, India , May 31, 2016 ... 2016" market research report with comparative analysis of Asthma ... mechanism of action (MoA), route of administration (RoA) and ... and press releases. It also reviews key players involved ... on late-stage and discontinued projects. Complete report ...
(Date:5/30/2016)... 30, 2016 According to ... Services Market by Type (Stability, Raw Materials, Method ... User (Pharmaceutical Companies, Medical Device Companies) - Global ... witnessed healthy growth during the last decade and ... 11.3% between 2016 and 2021 to reach USD ...
Breaking Medicine Technology:
(Date:5/31/2016)... Linda, CA (PRWEB) , ... ... ... an approach to healthcare that considers individuals’ genetic characteristics and the physical ... and precision therapy work in sync. In personalized medicine, diagnosing an individual’s ...
(Date:5/31/2016)... ... May 31, 2016 , ... St. Joseph Medical ... health information exchange, which enables physicians at SJMC’s two hospital campuses, downtown and ... participating organizations in the exchange. SJMC’s membership in the health information exchange underscores ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... back to particular advertising campaigns, to monitor the performance of sales and support ... maximize conversions and revenue. The software allows customers to record, transcribe, route, document, ...
(Date:5/31/2016)... ... May 31, 2016 , ... The Global Wellness Summit (GWS), ... on the future of wellness, travel, spa and beauty in Europe. The organization asked ... companies to leading economists and researchers - to forecast where wellness is headed in ...
(Date:5/31/2016)... ... ... Interest is on the rise for using the CRISPR-Cas9 system for functional ... hit validation. A key reason may be that high-throughput synthesis—combined with a proprietary algorithm ... collections in arrayed formats. , Arrayed crRNA screens have the advantage ...
Breaking Medicine News(10 mins):